Skip to content

Alumis Inc. ALMS Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Amgen logo
AmgenAMGN
-$959M-9.7%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$1.3M-156%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$437K+90.9%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$10.79M+8.7%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$7.21M+38.3%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$3.65M+161%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s change in accrued liabilities?
Alumis Inc. (ALMS) reported change in accrued liabilities of -$9.72M in Q1 2026.
How has Alumis Inc.'s change in accrued liabilities changed year-over-year?
Alumis Inc.'s change in accrued liabilities decreased by 294.8% year-over-year, from $4.99M to -$9.72M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.